Prevention of appendicular bone loss in Paget’s disease following treatment with intravenous pamidronate disodium
- 21 January 1999
- Vol. 24 (2), 139-144
- https://doi.org/10.1016/s8756-3282(98)00163-x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Alendronate in the treatment of Paget's disease of boneBone, 1997
- Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: A 2-year studyBone, 1996
- Comparative study of alendronate versus etidronate for the treatment of Paget's disease of boneJournal of Clinical Endocrinology & Metabolism, 1996
- Comparative prospective, double‐blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of paget's disease of boneArthritis & Rheumatism, 1995
- Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of paget's disease with pamidronate disodiumJournal of Bone and Mineral Research, 1993
- Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responsesClinical Endocrinology, 1991
- Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancyBone and Mineral, 1991
- Efficacious Management with Aminobisphosphonate (APD) in Paget??s Disease of BonePublished by Wolters Kluwer Health ,1987
- Long-term follow-up of therapy with intermittent etidronate disodium in paget's disease of boneThe American Journal of Medicine, 1985
- Modifications of a specific assay for hydroxyproline in urineAnalytical Biochemistry, 1967